Pharmaceuticals
India's Netmeds gets $45m Series C round
Indian online drug marketplace operator Netmeds has received a $45 million Series C funding round with participation from Russian venture capital investor Sistema Asia Fund.
GIC leads $85m Series B for China's Harbour BioMed
Harbour BioMed, a China-based biopharmaceutical company focused on treatments for cancer and autoimmune disorders, has raised an $85 million Series B round led by Singapore’s GIC Private.
China’s GL commits $12.5m to UK-listed healthtech platform
GL Capital, a healthcare-focused GP based in China, has invested GBP9.75 million ($12.5 million) in UK-listed health technology platform Oxford BioDynamics (OBD) as part of a larger partnership aimed at expansion in China.
CDH-backed Mabpharm files for Hong Kong IPO
Mabpharm, a China-based biopharmaceutical company backed by CDH Investments, has filed for an IPO in Hong Kong, the latest in a growing number of proposed listings under new rules that allow biotech companies with no revenue or profits to go public.
China’s Ascentage Pharma files for HK IPO
Ascentage Pharma, a Chinese biopharmaceutical company with several private equity backers, has filed for an IPO in Hong Kong.
China Biologic Products receives competing take-private offer
US-listed China Biologic Products has received a buyout offer worth $3.9 billion from a consortium including former CEO David Gao and CDH Investments. It follows a $3.6 billion bid last month by CITIC Capital.
Blackstone to invest $400m in Hong Kong-listed HEC Pharm
The Blackstone Group has agreed to invest $400 million in YiChang HEC Changjiang Pharmaceutical (HEC Pharm), a Chinese drug developer listed in Hong Kong, through a convertible bond issuance.
True North to acquire orthopedics division of India’s Glenmark
True North has agreed to acquire the Indian orthopedics and pain management business of drug maker Glenmark Pharmaceuticals at a valuation of INR6.4 billion ($91.8 million).
China's CureGenetics gets $17m Series A round
Qiming Venture Partners has led a $17 million Series A funding round for Chinese biotechnology company CureGenetics.
Decheng leads Series C for China's Impact Therapeutics
Chinese biopharmaceuticals developer Impact Therapeutics has raised $30 million in Series C funding from a group of investors led by Decheng Capital.
TPG invests in India's Sai, Tata Capital exits
TPG Capital has acquired a significant minority stake in Indian drug developer and manufacturer Sai Life Sciences, providing a full exit for Tata Capital Growth Fund.
China's Ascentage Pharma gets $150m in Series C funding
Ascentage Pharma, a Chinese biopharmaceutical company primarily focused on treatments for cancer, has raised $150 million in Series C funding.
China's Yunfeng buys German pharma player
China’s Yungfeng Capital has teamed up with Shenzhen-based Hybio Pharmaceutical to acquire diversified German biopharmaceuticals company AMW for an undisclosed sum.
Cancer drug developer Innovent Biologics files for HK IPO
Innovent Biologics, a Chinese drug developer company with a number of PE backers, has filed for an IPO in Hong Kong under recently introduced rules allowing listings by biotech companies with no revenue or profits.
C-Bridge leads $20m round for China's Nuance
C-Bridge Capital, a Chinese healthcare-focused private equity firm, has led a $20 million Series B funding round for domestic pharmaceuticals developer Nuance Biotech.
Hong Kong biotech IPOs: Capital injection
The move to allow zero-revenue biotech companies to list in Hong Kong has spurred investor interest in healthcare. But valuations are high and success in this capital-intensive space is by no means guaranteed
Qiming leads $37m round for China's Alpha Biopharma
China’s Qiming Venture Partners has led a $37 million Series A investment in domestic biopharmaceutical start-up Alpha Biopharma.
Pivotal China seeds Sino-US cancer drug developer
Pivotal BioVenture Partners China, an investment platform of Hong Kong conglomerate Nan Fung Group, has led a $16.5 million seed round for Sino-US cancer drug developer Oncologie.
Brii Biosciences gets $260m for China expansion
A group of VCs, including Sequoia Capital, have committed $260 million to Brii Biosciences, a China and US-based healthcare start-up executing a number of China-focused growth initiatives.
GIC leads $260m round for China’s CStone Pharma
Singapore’s GIC Private has led a $260 million Series B investment in China’s CStone Pharmaceuticals. The round, completed within two months, is said to be the largest biopharma Series B in the country to date.
Lilly Asia leads $25m round for US-based Avedro
Lilly Asia Ventures (LAV) has led a $25 million round for Avedro, a US-based ophthalmic pharmaceutical and medical devices company with a view to expanding in Asia.
Capital Group leads Series E for China’s Innovent Biologics
Capital Group Private Markets (CGPM), a private equity affiliate of US-based Capital Group Companies, has led a $150 million Series E round for Chinese biopharmaceutical developer Innovent Biologics.
Chinese VCs in $11m round for US-based NuProbe
Sequoia Capital China and Serica Partners have co-led an $11 million Series A round for US-based molecular diagnostics start-up NuProbe.
China's CMAB Biopharma gets $34m Series B
CD Capital, a Chinese healthcare-focused VC also known as CDBI Partners, has led a $34 million Series B round for CMAB Biopharma, a manufacturing services provider for biologic product developers.